Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Completed · Phase 1

Conditions studied: Myeloid Leukemia

In brief

The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.

Key facts

Study ID

NCT00497991

Run by

AstraZeneca

People needed

65

Starts

2006-05-01

Expected to finish

2010-04-01

Last updated by the study team

2010-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission
• Newly diagnosed AML who are not considered suitable for other treatments.

You may not qualify if…

• Previous myeloablative therapy allogeneic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose.
• Participation in any other trial with an investigational product within the previous 30 days
• Other active malignancy.

Where it is running

• Research Site — New York, New York, United States
• Research Site — Houston, Texas, United States
• Research Site — Angers, France
• Research Site — Grenoble, France
• Research Site — Le Chesnay, France
• Research Site — Bologna, Italy
• Research Site — Roma, Italy
• Research Site — Amsterdam, Netherlands
• Research Site — Nijmegen, Netherlands
• Research Site — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.